WILMINGTON, Del., July 16, 2024 /PRNewswire/ -- SPI Pharma, Inc. a
global leader in biopharmaceutical excipient and adjuvant systems,
and Inimmune, Corp., a pioneering biotechnology company
specializing in the discovery and development of innate immune
modulators, announce an agreement in principle to create a
strategic collaboration to develop and commercialize advanced
adjuvant systems for vaccine development. This collaboration
leverages Inimmune's world-class expertise in adjuvant formulation
and immunotherapeutics and SPI Pharma's extensive manufacturing and
global commercial capabilities.
Adjuvant systems are critical components of vaccines that
enhance immune response and efficacy. The partnership will aim to
provide reliable supply and open access to advanced adjuvant
systems, addressing significant unmet needs in vaccine development
and accelerating the availability of these technologies to
healthcare providers and patients globally.
"Inimmune's dedication to advancing immunological research
coupled with SPI Pharma's robust commercial infrastructure creates
a powerful synergy," said John
McInerney, Vice President of Commercial for SPI Pharma.
"Together, we are poised to deliver innovative solutions that can
potentially transform vaccine efficacy and patient outcomes
worldwide."
"We are excited to collaborate with SPI Pharma to bring our
vaccine adjuvant technologies to market," said Alan Joslyn, Ph.D., CEO of Inimmune. "This
partnership underscores our shared commitment to improving public
health through innovation."
About Inimmune: Inimmune Corp. (Missoula, MT) is a privately held clinical
stage biotechnology company focused on the discovery and
development of innovative immunotherapeutics, vaccine adjuvants and
vaccines. Inimmune is harnessing the human immune system via novel
innate immune modulators to create safe and effective treatments
for allergy, infectious disease, autoimmunity and cancer. Their
laboratories and offices are housed in the Montana Technology
Enterprise Center (MonTEC) in Missoula. For more information
on Inimmune's research and development of novel vaccine adjuvants
and delivery systems, please visit www.inimmune.com.
About SPI Pharma: SPI Pharma, headquartered in Wilmington, Delaware, USA, provides innovative
products and technical solutions to global pharmaceutical
customers. Product lines include Vaccine Adjuvant Systems, Drug
Delivery Systems, Antacid Actives, Taste Masking and Excipients.
SPI Pharma specializes in drug development services, having
participated in over 60 commercially launched and marketed drugs
globally. With its sites in the United
States, France, and
India, the company solves the most
challenging formulation problems –– efficiently, cost-effectively,
and with a focus on service. For more information, visit
www.spipharma.com.
Inimmune contact information:
Alan Joslyn
CEO
Inimmune Corp
info@inimmune.com
SPI Pharma contact Information:
Donald Loveday
Global Business Development Manager
SPI Pharma
dloveday@spipharma.com
Logo -
https://mma.prnewswire.com/media/2461708/spi_and_inimmune_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/spi-pharma-inc-and-inimmune-corp-partner-to-develop-and-commercialize-innovative-vaccine-adjuvant-systems-302198100.html